The UK policy action blueprint, accompanying situation analysis report and supporting materials were developed in collaboration with a UK Expert Advisory Group. The multidisciplinary group had full editorial control over content of these materials, which reflect group consensus. All members provided their time for free.

We would like to thank group members for their contribution:

Advisory Group UK Radioligand Therapy Readiness Assessment Framework
John Buscombe

Dr John Buscombe

Locum Consultant Physician in Nuclear Medicine, Barts Health NHS Trust; International Neuroendocrine Cancer Alliance

Nikie Jervis

Nikie Jervis

Senior Patient Support, Information Nurse Specialist and Education Lead, Neuroendocrine Cancer UK

J Bomanji

Professor Jamshed Bomanji

Head of Clinical Department, Institute of Nuclear Medicine, UCLH NHS Foundation Trust

G Flux

Dr Glenn Flux

Head of Radioisotope Physics, Royal Marsden Hospital

R Gill

Ropinder Gill

Chief Executive, Lymphoma Action

Advisory Group UK

Professor Neil Hartman

Head of Nuclear Medicine, Swansea Bay University Health Board, Swansea University

A Lamarca

Dr Angela Lamarca

Consultant in Medical Oncology, The Christie NHS Foundation Trust, University of Manchester

H Payne

Professor Heather Payne

Consultant in Clinical Oncology, University College Hospital, British Uro-oncology Group, Oncology Lead for the National Prostate Cancer Audit

K Stalbow

Karen Stalbow

Head of Policy, Knowledge and Health Information, Prostate Cancer UK

Get in touch

For more information about this project contact us:

We’re on Twitter! Follow @radioligand¬†for updates on this project and other exciting developments in targeted cancer care.